Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 5, 2023

Discussion on the mechanism of action of Salvia miltiorrhiza in the treatment of prostate cancer based on network pharmacology

Download as PDF

DOI: 10.23977/medsc.2023.040515 | Downloads: 10 | Views: 355

Author(s)

Jiajun Chen 1, Xuelin Tan 2, Yuting Bai 3, Xin Chen 4

Affiliation(s)

1 Department of Clinical Laboratory, Gaoping District People's Hospital of Nanchong, Nanchong, China
2 Department of Clinical Laboratory, Nanchong Central Hospital Affiliated to North Sichuan Medical College, Nanchong, China
3 Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
4 Department of Rehabilitation Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, China

Corresponding Author

Xin Chen

ABSTRACT

The purpose of this study was to explore the mechanism of action of Salvia miltiorrhiza in the treatment of prostate cancer (PCa) based on the network pharmacology approach, and to provide a basis for rational clinical use and cellular experiments. The method used in this study was to obtain the main active components and corresponding targets of Salvia miltiorrhiza through the Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP), Perl, UniProt and other databases. Disease targets for PCa were obtained from GeneCards, OMIM, TTD and DrugBank databases. Using bioinformatics online database mapping tool, Venn diagram was drawn to screen the cross targets of Salvia miltiorrhiza and PCa active components. active components of Salvia miltiorrhiza-PCa related target network and cross target protein interaction (PPI) network were constructed using STRING platform, and Cytoscape 3.8.2 software was used to screen key targets, and R 4.3.0 software was used to perform gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. A total of 58 active components of Salvia miltiorrhiza and their corresponding target genes and 2142 target genes related to PCa were obtained. The results of Venn diagram showed that there were 74 cross targets between the active components of Salvia miltiorrhiza and PCa. Luteolin, tanshinone, quercetin and dihydrosalvia miltiorrhiza lactone may be the important nodes of the active components of Salvia miltiorrhiza-PCa related target network, while MAPK14, MYC, TP53, ESR1 and JUN may be the key targets of PPI network. The results of GO analysis showed that the cellular components of 74 targets of Salvia miltiorrhiza in the treatment of PCa were mainly nuclear, chromatin and cytoplasm, and the biological processes were mainly negative regulation of apoptosis, the response to xenobiotic stimulus, and the positive regulation of cell proliferation, and so on. Molecular functions mainly include enzyme binding process, protein binding process, regulation of protein homodimer activity, binding protein kinase and so on. KEGG pathway enrichment analysis showed that the cross targets were mainly concentrated in cancer signaling pathway, prostate cancer signaling pathway, PI3K-Akt signaling pathway, IL-17 signaling pathway, HIF-1 signaling pathway and so on. This study preliminarily reveals the molecular and cellular pathway mechanism of Salvia miltiorrhiza in the treatment of PCa, which provides a scientific basis for clinical use and a reference direction for follow-up cell experiments.

KEYWORDS

Network pharmacology, Prostate cancer, Mechanism, Salvia miltiorrhiza

CITE THIS PAPER

Jiajun Chen, Xuelin Tan, Yuting Bai, Xin Chen, Discussion on the mechanism of action of Salvia miltiorrhiza in the treatment of prostate cancer based on network pharmacology. MEDS Clinical Medicine (2023) Vol. 4: 106-114. DOI: http://dx.doi.org/10.23977/medsc.2023.040515.

REFERENCES

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70:7-30. 
[2] Krahn MD, Bremner KE, Zagorski B, Alibhai SM, Chen W, Tomlinson G, et al. Health care costs for state transition models in prostate cancer. Med Decis Making. 2014; 34:366-78. 
[3] Krahn MD, Bremner KE, Luo J, Alibhai SM. Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events. Curr Oncol. 2014; 21:e457-65. 
[4] Xinyu X, Pengfei G, Yun YZC, Fugui J, Zecheng S, Jiahao L, et al. Research Progress of Traditional Chinese Medicine in Treatment of Prostate Cancer. Shandong Journal of Traditional Chinese Medicine. 2022; 41:806-9. 
[5] Xiuyue W, Chuan Z, Wenjing L, Che C, Yong W, Huiyuan C, et al. Progress in search for mechanism of Tanshinone ⅡA's against colon cancer The Chinese Journal of Clinical Pharmacology. 2018; 34:597-9. 
[6] Daorong H, Zhen L, Sitong C, Jun M. Tanshinonell-A inhibits LPS induced inflammation of RAW264. 7 cells byregulating TLR4/lkB-a/NF-KB signaling pathway. Chinese Pharmacological Bulletin. 2021; 37:210-4. 
[7] Zhou J, Zhang L, Zheng B, Zhang L, Qin Y, Zhang X, et al. Corrigendum to “Salvia miltiorrhiza bunge exerts anti-oxidative effects through inhibiting KLF10 expression in vascular smooth muscle cells exposed to high glucose” [J. Ethnopharmacol. 262 (2020) 113208]. J Ethnopharmacol. 2021; 279:114159. 
[8] Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014; 6:13. 
[9] Wang Y, Wang Q, Huang H, Huang W, Chen Y, McGarvey PB, et al. A crowdsourcing open platform for literature curation in UniProt. PLoS Biol. 2021; 19:e3001464. 
[10] Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1. 30. 1-1. . 3. 
[11] Amberger JS, Hamosh A. Searching Online Mendelian Inheritance in Man (OMIM): A Knowledgebase of Human Genes and Genetic Phenotypes. Curr Protoc Bioinformatics. 2017; 58:1. 2. 1-. 2. 12. 
[12] Chen X, Ji ZL, Chen YZ. TTD: Therapeutic Target Database. Nucleic Acids Res. 2002; 30:412-5. 
[13] Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006; 34:D668-72. 
[14] Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47:D607-d13. 
[15] Reimers M, Carey VJ. Bioconductor: an open source framework for bioinformatics and computational biology. Methods Enzymol. 2006; 411:119-34. 
[16] Chen M, Zhu J, Kang J, Lai X, Gao Y, Gan H, et al. Exploration in the Mechanism of Action of Licorice by Network Pharmacology. Molecules. 2019; 24. 
[17] Yan R, Yan-jun D, Han-bin M, Rong-lei Z, Meng Y, An-di Y, et al. Research progress and challenges of network pharmacology in field of traditional Chinese medicine. Chinese Traditional and Herbal Drugs. 2020; 51:4789-97. 
[18] Du Y, Feng J, Wang R, Zhang H, Liu J. Effects of Flavonoids from Potamogeton crispus L. on Proliferation, Migration, and Invasion of Human Ovarian Cancer Cells. PLoS One. 2015; 10:e0130685. 
[19] Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008; 8:634-46. 
[20] Fang J, Zhou Q, Shi XL, Jiang BH. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis. 2007; 28:713-23. 
[21] Li C, Han X, Zhang H, Wu J, Li B. The interplay between autophagy and apoptosis induced by tanshinone IIA in prostate cancer cells. Tumour Biol. 2016; 37:7667-74. 
[22] Zhang T, Rong N, Chen J, Zou C, Jing H, Zhu X, et al. SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. PLoS One. 2013; 8:e79162. 
[23] Ko H, Jeong MH, Jeon H, Sung GJ, So Y, Kim I, et al. Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage. Oncotarget. 2015; 6:9970-84. 
[24] Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol. 2012; 19:2011-9. 
[25] Schulze-Osthoff K, Bantel H. Macrophage p38 kinase inhibition for liver regeneration. Febs j. 2017; 284:4196-9. 
[26] Chen YJ, Chen HP, Cheng YJ, Lin YH, Liu KW, Chen YJ, et al. The synthetic flavonoid WYC02-9 inhibits colorectal cancer cell growth through ROS-mediated activation of MAPK14 pathway. Life Sci. 2013; 92:1081-92. 
[27] Kim CG, Castro-Aceituno V, Abbai R, Lee HA, Simu SY, Han Y, et al. Caspase-3/MAPK pathways as main regulators of the apoptotic effect of the phyto-mediated synthesized silver nanoparticle from dried stem of Eleutherococcus senticosus in human cancer cells. Biomed Pharmacother. 2018; 99:128-33. 
[28] Li B, Simon MC. Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res. 2013; 19:5835-41. 
[29] Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov. 2013; 3:1156-71. 
[30] Link JM, Ota S, Zhou ZQ, Daniel CJ, Sears RC, Hurlin PJ. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis. Proc Natl Acad Sci U S A. 2012; 109:19685-90. 
[31] Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, et al. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013; 19:5777-87.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4588
Visits: 199338

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.